logo
Plus   Neg
Share
Email

AstraZeneca : Lynparza Receives Positive EU CHMP Opinion

AstraZeneca (AZN.L,AZN) and Merck & Co. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of Lynparza (olaparib) tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.

Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

The positive opinion is based on data from the randomised, open-label, Phase III OlympiAD trial, which tested Lynparza against the physician's choice of chemotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has removed four separate networks of accounts, pages and groups for engaging in co-ordinated inauthentic behavior on Facebook and Instagram. These networks originated from Iran and Russia and primarily targeted the US, North Africa and Latin America. These networks often posted on both sides of political issues including topics like US elections, environmental issues, racial tensions. While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020.
Follow RTT
>